ArticleBioengineering (Basel, Switzerland)2024
NMGrad: Advancing Histopathological Bladder Cancer Grading with Weakly Supervised Deep Learning.
Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A multi-modal approach for decision making in bladder cancer.Nature reviews. Urology · 2026Review
- Artificial intelligence-assisted diagnosis and histopathological grading of bladder cancer: current status, challenges, and future directions.Frontiers in digital health · 2026Review
- Artificial intelligence in genitourinary pathology.Histopathology · 2026Review
- Artificial intelligence-driven digital pathology in urological cancers: current trends and future directions.Prostate international · 2025Review
- Multi-institutional validation of AI models for classifying urothelial neoplasms in digital pathology.Scientific reports · 2025Article
- Computational pathology in bladder cancer: A scoping review.Bladder cancer (Amsterdam, Netherlands)Review
- LLM-BCgrading: Large language model-based Chinese medical long text classification for bladder cancer grade prediction.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The most prevalent form of bladder cancer is urothelial carcinoma, characterized by a high recurrence rate and substantial lifetime treatment costs for patients. Grading is a prime factor for patient risk stratification, although it suffers from inconsistencies and variations among pathologists. Moreover, absence of annotations in medical imaging renders it difficult to train deep learning models. To address these challenges, we introduce a pipeline designed for bladder cancer grading using histological slides. First, it extracts urothelium tissue tiles at different magnification levels, employing a convolutional neural network for processing for feature extraction. Then, it engages in the slide-level prediction process. It employs a nested multiple-instance learning approach with attention to predict the grade. To distinguish different levels of malignancy within specific regions of the slide, we include the origins of the tiles in our analysis. The attention scores at region level are shown to correlate with verified high-grade regions, giving some explainability to the model. Clinical evaluations demonstrate that our model consistently outperforms previous state-of-the-art methods, achieving an F1 score of 0.85.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.